Lutetium Lu-177 PNT2002

Phase 3Radiopharmaceutical

Lutetium Lu-177 PNT2002 is one of 101 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaRecruiting

Prostate CancerRecruiting

McrpcActive, not recruiting

Castration-Resistant Prostate CarcinomaRecruiting

Metastatic Castration-Resistant Prostate CarcinomaRecruiting

Prostate AdenocarcinomaPhase 2

Recruiting

Prostate CancerPhase 3

Recruiting

McrpcPhase 2

Active, not recruiting

Castration-Resistant Prostate CarcinomaPhase 2

Recruiting

Metastatic Castration-Resistant Prostate CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Alinamin

Roche

Phase 3

6 3

Acetylsalicylic Acid

Bayer

Phase 3

2 4

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 5

Semaglutide Pen Injector

UUniversitaire Ziekenhuizen KU Leuven

Phase 3

1 6

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 7

INR101

YYunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

3 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Mcrpc

NCT05682443

Q4 2027

Phase 2Recruiting

Castration-Resistant Prostate Carcinoma

NCT06145633

Phase 2Recruiting

Metastatic Castration-Resistant Prostate Carcinoma

NCT06526299

Q1 2028

Phase 2Recruiting

Prostate Cancer

NCT06288113

Q3 2028

Phase 1Recruiting

Prostate Cancer

NCT07219147

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06288113·40 enrolled

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06216249·90 enrolled

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting·—·Phase 1·NCT07219147·30 enrolled

Show 1 more trial

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT05496959·93 enrolled

Castration-Resistant Prostate Carcinoma3 trials

PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT06632977·474 enrolled

Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer

Suspended·MMayo Clinic·Phase 2·NCT06200103·236 enrolled

Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06145633·15 enrolled

Metastatic Castration-Resistant Prostate Carcinoma2 trials

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT07200830·1,524 enrolled

A Phase 2 Study of Biomarker-Modulated PSMA Theranostics

Recruiting·UUniversity of Washington·Phase 2·NCT06526299·51 enrolled

mCRPC1 trial

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Active, not recruiting·OOncoC4, Inc.·Phase 1/2·NCT05682443·148 enrolled

Prostate Adenocarcinoma1 trial

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07150715·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lutetium Lu-177 PNT2002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium Lu-177 PNT2002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium Lu-177 PNT2002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 3[1]
Company: JJonsson Comprehensive Cancer Center

Lutetium Lu-177 PNT2002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Prostate Cancer4 trials

Castration-Resistant Prostate Carcinoma3 trials

Metastatic Castration-Resistant Prostate Carcinoma2 trials

mCRPC1 trial

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News